Welcome to Bleacher Report's Top 100 NBA Player Rankings for the 2025-26 season. The following list isn't built from advanced analytics, complex formulas or A.I. assistance. Instead, it's driven by ...
Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback